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Objective: The aim of this paper is to report midterm results of thoracic endovas-
cular aortic repair (TEVAR) for ascending aortic pseudoaneurysms (AAPs) and
penetrating aortic ulcers (PAUs) of the ascending aorta.
Methods: This study was retrospective and performed at tertiary centers. Eight
patients with AAPs (n ¼ 5) and PAUs (n ¼ 3) received total endovascular repair
of the ascending aorta. Patients with a history of type A aortic dissection or fusi-
form aneurysmwere excluded. All patients analyzed were considered to be at high
risk for open repair at the time of presentation.
Results: Urgent intervention was performed in 6 (75%) cases. Primary clinical
success was achieved in 7 (87.5%) cases. A low-flow type 3 endoleak remained
asymptomatic and was managed conservatively. No TEVAR-related in-hospital
mortality, primary conversion, cerebrovascular accidents, valve impairment, or
myocardial infarction occurred. All patients were discharged home, alive and
independent, after a median length of stay of 6 (range: 5-24) days. No patient
was lost at a mean follow-up of 40  33 (range: 4-93) months. Ongoing primary
clinical success was maintained in all but 1 patient (type 3 endoleak): aortically
related reintervention was never required. No endograft breakage or migration
was observed. At 1-year follow-up, 7 (87.5%) aortic lesions had significant
reduction in diameter (5 mm).
Conclusions: Ascending TEVAR was feasible, safe, and effective for AAPs
and PAUs. In a very select subset of lesions, midterm results were favorable,
with both standard and custom-designed endografts. (J Thorac Cardiovasc Surg
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Central Message
Ascending TEVAR was feasible, safe, and
effective for a subset of pseudoaneurysms and
penetrating ulcers, with favorable midterm
results.Perspective
Thoracic endovascular aortic repair has
emerged as an alternative method of treatment
for thoracic aortic diseases. The ascending
aorta is the new ‘‘frontier’’ of TEVAR. In a
very select subset of lesions, TEVAR may be
preferred for patients who may not be able to
tolerate a complex and risky operation, or it
can be adopted as a bridge treatment, making
emergent into elective interventions.See Editorial Commentary page 1615.
g aorta has been targeted as the newThoracic endovascular aortic repair (TEVAR) has evolved
rapidly, becoming an effective alternative to open repair
for descending and aortic arch pathologies.1,2 Morerecently, ascendin
frontier of endovascular repair, and currently, few
series of ascending TEVAR have been reported.3-8
Although several technical concerns remain, including
anatomical landmarks, hemodynamic forces, and
endograft performance, favorable results have been
reported in a very select group of morphologies.5-8
Ascending aortic pseudoaneurysms (AAPs) are an
uncommon, but potentially life-threatening, complication
after aortic surgery; however, regardless of the etiology,
reoperation for AAPs entails a hospital mortality rateQR code will take
cle title page.
Abbreviations and Acronyms
AAP ¼ ascending aortic pseudoaneurysm
EuroSCORE ¼ European system for cardiac
operative risk evaluation
PAU ¼ penetrating aortic ulcer
TEE ¼ transesophageal echocardiography
TEVAR ¼ thoracic endovascular aortic repair
Piffaretti et al Acquired: Aortaof 6.9% to 15.4%, even in experienced centers.9,10
Similarly, penetrating aortic ulcer (PAU) of the ascending
aorta has not been reported frequently, but it has exhibited
a high risk of rupture at presentation and an in-hospital
mortality rate of up to 16%.11 Pseudoaneurysms and
PAUs are usually saccular lesions of the aorta, which proved
to be an attractive site for TEVAR, because of the focal
involvement of the aortic wall, and can be effective in
high-risk patients.3,12 The aim of the current paper is to
report midterm results of TEVAR for pseudoaneurysms




Patient Cohort and Preoperative Procedures
This study is retrospective, involving 2 cardiovascular surgery units at
referring tertiary hospitals. All patients were identified who had AAP
and PAU and received total TEVAR of the ascending aorta between 2006
and 2014. Patients with type A aortic dissection or fusiform aneurysm of
the ascending aorta were excluded from this case series. All patients
analyzed were considered to be at high risk for open repair at the time of
presentation, because of the EuroSCORE, the performance status, and
the opinions expressed in a multidisciplinary team debate (among cardiac
and vascular surgeons, interventional cardiologists, and anesthesiology
staff).13 The protocol and informed consent were approved by the
institutional review board; after a detailed discussion on the risks and
benefits of an open repair versus an endovascular alternative, informed
consent to proceed with TEVAR was obtained from all patients. Complete
thoracoabdominal computed tomography angiography was performed in
all cases, to evaluate the anatomy of the ascending aorta and optimize
endograft selection. The type of endograft was determined by the
ascending aortic length and the diameter, measured immediately above
the sinotubular junction (proximal landing zone at the tubular portion of
the ascending aorta). Supra-aortic trunk and brain vessels were evaluated
to assess both the integrity of the Willis circle and the dominance of the
vertebral arteries, as well as to plan aortic arch debranching if needed.
Operative Technique
The TEVAR procedure was performed with patients under general
anesthesia, with the cardiac perfusion team on standby to assist if needed;
transesophageal echocardiography (TEE) monitoring was used in all cases.
During the intervention, intravenous weight-adjusted heparinization was
administered, to maintain an activated clotting time of 250 seconds
throughout the procedure. The endograft insertion site was selected
depending on sizing of the access artery, device characteristics, and
ascending/arch anatomy. Preliminary angiography was performed in all
cases, to identify the ostium of the coronary arteries and the brachioce-
phalic trunk takeoff point; the brachiochephalic trunk was the anatomical
border of the distal landing zone. During the advancement of the
endograft, TEE confirmed the absence of valve impairment; in all cases,The Journal of Thoracic and Carthe endograft was deployed under temporary overdrive cardiac pacing
(generally, 190 bt/min), via a transvenous pacing catheter. Considering
both the fact that we treated either native or ‘‘grafted’’ aortas, and the focal
nature of these lesions, we chose to use a 10% to 15% range of oversizing,
to prevent endograft-induced retrograde dissection. Final control
angiography and TEE were used to confirm the exclusion of the aortic
lesion, competency of the aortic valve, and patency of the coronary arteries
and the supra-aortic vessels.
Postoperative Protocol
Postoperatively, every patient started clopidogrel bisulfate at 75 mg per
day, plus aspirin (Cardioaspirin; Bayer, Rome, Italy) at 100 mg; alterna-
tively, warfarin sodium (Coumadin; Bristol-Myers Squibb, Rome, Italy)
at 5 mg was used for patients who were already on an anticoagulant
regimen preoperatively. Transthoracic echocardiogram and computed to-
mography angiography were performed before discharge. Follow-up imag-
ing included chest radiographs and triple-phase computed tomography
angiography at 1, 4, and 12 months after intervention, and annually there-
after. Either abdominal and thoracic standard devices (Excluder;W.L. Gore
and Associates, Flagstaff, Ariz, and TX-2; Cook, Bloomington, Ind) or a
custom-designed endograft (Relay; Bolton Medical, Sunrise, Fla) were
implanted.
Definition
All variables analyzed in the study were defined according to the
Society of Thoracic Surgeons adult database.14 Morphological characteris-
tics and outcomes were classified according to the Society for Vascular
Surgery ad hoc committee on TEVAR reporting standards.15 The location
of the aortic lesion was described according to the various segments of the
ascending aorta: ‘‘zone 1’’ includes the aortic root, sinotubular junction,
and proximal third of the tubular portion of the ascending aorta; ‘‘zone
2,’’ which does not have any branches, corresponds to the middle-third
tubular portion of the ascending aorta; and ‘‘zone 3’’ represents the distal
third tubular portion of the ascending aorta, reaching the proximal aspect
of the brachiocephalic trunk.16 Clinical data were prospectively recorded.
Results are expressed as mean  standard deviation for continuous
variables, and frequencies for categorical ones.RESULTS
Patient Data
We treated 8 patients: 6 (75%) were men, with mean age
71  7 (range: 58-81) years. Comorbidities and risk factors
are shown in Table 1. Six (75%) patients had a history of
previous major cardiac operation; median delay from the
first cardiac operation was 12 (range: 6-108) months.
Indications for TEVAR were AAP (n ¼ 5) and PAU
(n ¼ 3). Etiology of AAP included cannulation site
(n¼ 4) and suture line disruption (n¼ 1); AAPwas mycotic
in 1 case. All PAUs were degenerative in etiology. Overall, 5
(62.5%) patients were symptomatic for acute thoracic pain.
Two AAPs were asymptomatic, detected during follow-up
examinations (Figure 1). Aortic lesion was located in
‘‘zone 1’’ in 1 (12.5%) case, ‘‘zone 2’’ in 5 (62.5%), and
‘‘zone 3’’ in 2 (25%). The mean maximum aortic lesion
diameter was 48  15 (range: 20-70) mm. The proximal
ascending aorta diameter at the proximal landing zone
was 32  7 (range: 22-41) mm. The mean distance
between the coronary arteries/bypass graft ostia and the
brachiocephalic trunk was 74.5  7 (range: 48-90) mm.diovascular Surgery c Volume 151, Number 6 1607
TABLE 1. Comorbidities and risk factors of the cohort




CRI (CKD stage 3-4) 4 (50)
COPD (GOLD stage 2) 3 (37.5)
Valve disease 2 (25)
CVA 2 (25)
Atrial fibrillation 2 (25)





EuroSCORE 13.5  5.1 (8.5-23.8)
SD, Standard deviation; IHD, ischemic heart disease; CRI, chronic renal
insufficiency; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary
disease;GOLD, Global Initiative for Chronic Obstructive Lung Disease; CVA, history
of cerebrovascular accidents; CABG, coronary artery bypass graft; EuroSCORE, Eu-
ropean system for cardiac operative risk evaluation.





Urgent intervention was performed in 6 (75%) cases. The
right common femoral artery access was used in 5 (62.5%)
cases, the left subclavian artery in 2 (25%), and a right
subclavian artery in 1 (12.5%). A summary of operative
details is shown in Table 2. A standard endograft was
used in 6 (75%) cases; 1 of the 2 custom-designed
endografts was reversed tapered. The mean endograft
diameter was 40  6 (range: 30-50 mm), and the mean
length was 58  10 (range: 45-70) mm. Five (62.5%)
patients received 1 endograft; 3 (37.5%) received 2
endografts. An additional procedure was required in 1
(12.5%) patient: a common femoral endarterectomy with
patch plasty was needed at the end of the procedure after
retrieval of the device.In-Hospital Results
Primary clinical success was achieved in 7 (87.5%)
patients. One patient with an acute symptomatic PAU
treated with multiple endografts had a type 3 endoleak
at the end of the intervention. This endoleak was late
in appearance and with a very limited reperfusion of
the aortic lesion. No TEVAR-related in-hospital mortal-
ity occurred. Primary conversion was never required.
TEVAR-related complication included 1 (12.5%) mild
event: A femoral pseudoaneurysm was successfully
excluded with a thrombin injection. The low-flow type
3 endoleak remained asymptomatic and was managed
conservatively. Cerebrovascular accidents, valve impair-
ment, and myocardial infarction did not occur. All
patients were discharged home, alive and independent.
The median length of stay was 6 (range: 5-24) days.1608 The Journal of Thoracic and Cardiovascular SurThe patient with the mycotic AAP remained on lifelong
antibiotic therapy, given the risk of life-threatening
endograft infection.
Late Results
No patient was lost at a mean follow-up of 40  33
(range: 4-93) months. Ongoing primary clinical success
was maintained in all patients. Specifically, aortically
related reintervention, either open or endovascular, was
never required. No patient died during follow-up. Endograft
breakage, migration, and superinfection were not observed.
Of the 8 devices implanted, 7 (87.5%) had appropriate
follow-up imaging for evaluation at 1 year, 5 (62.5%) at
3 years (Figure 2), and 3 (37.5%) at 5 years (Figure 3).
At 1-year follow-up, 7 (87.5%) aortic lesions had
significant reduction in diameter (5 mm). The type 3
endoleak is still under surveillance, but neither shrinkage
nor sac enlargement was observed (Figure 4).
DISCUSSION
Pseudoaneurysms and PAUs are saccular lesions that
occur in rare cases at the ascending aorta.3,5,11,17
Although AAPs most frequently develop from
cannulation sites or graft suture lines in patients who have
a history of cardiac operations, PAUs are generally a
natural evolution of an atherosclerotic plaque rupture of
the aortic wall.4,8,11 Most authors agree that, regardless of
their etiology, these lesions should be managed
operatively—AAPs because of life-threatening complica-
tions after their formation, and PAUs because of their
high propensity to rupture despite optimal medical
management.4,10,11 However, open repair of AAPs carries
high risk owing to reoperation, whereas operative risk of
PAUs is mainly related to the multiple comorbidities the
patients bring with them.9-11 For these focal lesions,
TEVAR emerged as a potential alternative to redo open
repair, especially for high-risk patients. TEVAR avoids
the risks of repeat exposure and minimizes the adverse
effects of complex maneuvers in patients who are typically
older and have important risk factors. We have identified 40
cases of AAPs and PAUs treated with TEVAR so far:
TEVAR-related mortality was 5%, which is significantly
lower than the 6.9% to 15.4% for conventional open repair,
even at centers with highly experienced surgeons.4-8,18-26 In
particular, the rapidity and minimal invasiveness of TEVAR
could add value, in an emergent setting or for patients who
may not have tolerated a complex and risky operation, or
may be adopted as a bridge treatment, to change an
emergent intervention into an elective one.7
In a large cohort series, the ruptured rate of ascending
PAUs at presentation has been reported to be as much as
38%; they required urgent operation in 20% to 45% of
cases.9-11 In our case series, no patient presented with
aortic rupture, but 75% of the cases were treated urgentlygery c June 2016
FIGURE 1. Preliminary computed angiography of a suture-line disruption AAP (patient #7) shows the following: (A) the variant of the supra-aortic vessels
with a common origin of the brachiocephalic trunk and left common carotid artery; (B) the origin (arrow) of the AAP (marked as P) developed from a
previous ascending aortic graft replacement (marked as A); (C) multiplanar reconstruction; (D) volume rendering reconstruction indicating the enormity
of the pseudoaneurysm. BCT, Brachiocephalic trunk; LCCA, left common carotid artery; LSA, left subclavian artery; P, pseudoaneurysm; A, aorta.




because of typical symptoms of the acute aortic syndrome.
Although the preoperative score predicted a mean 13.5%
mortality rate, in-hospital mortality did not occur and all pa-
tients were discharged to home and independent living.
Thoracic endovascular aortic repair is a recent
application for ascending aortic diseases; therefore,





type Etiology Infection Symptomatic TEVAR
Male 57 CABG Cannulation No No Elective
Male 71 BAV Cannulation No Thoracic pain Urgent
Male 73 CABG PAU No Thoracic pain Urgent
Male 81 no PAU No Thoracic pain Urgent
Female 73 BAV cannulation No Thoracic pain Urgent
Male 65 CABG Cannulation Yes Thoracic pain Urgent
Female 75 Bentall Suture line No No Elective
Male 70 no PAU No Thoracic pain Urgent
Diameters and distance are given in mm. CS, (previous) Cardiac surgery; TEVAR, thoracic
evaluation; ASCAD, ascending aorta diameter; CA-IA, coronary arteries ostia-to-innomina
bypass graft; CM, custom-designed; BAV, biological aortic repair; OS, off-the-shelf; PAU,
The Journal of Thoracic and Carseries of ascending TEVAR, the reintervention rate at
12 months has been reported to be between 16.7% and
27%.4,7,8 Our results compare favorably: at longer follow-
up times, we did not observe aortically related mortality
or a need for reintervention; remarkably, a stable exclusion
or shrinkage of the aortic lesion was observed in nearly





8.80 20 26 70 CM 30 3 65 1
9.93 70 30 80 OS 36 3 45 3
8.46 53 35 75 OS 45 3 50 1
11.75 60 41 83 OS 45 3 60 1
16.49 35 37 90 OS 45 3 60 2
14.49 41 39 80 OS 45 3 70 1
23.79 53 22 70 CM 38-48 3 70 1
14.25 50 29 48 OS 36 3 45 4
endovascular aortic repair; EuroSCORE, European system for cardiac operative risk
te artery distance; EG, endograft; EGD, endograft diameter; CABG, coronary artery
penetrating aortic ulcer.
diovascular Surgery c Volume 151, Number 6 1609
FIGURE 2. Postoperative computed tomography-angiography control of Figure 1 AAP: (A) regular patency of the supra-aortic vessels with the distal edge
(arrow) of the custom-designed endograft deployed in proximity to the brachiocephalic trunk take-off point; (B) complete exclusion of the AAP (marked as
P), and full expansion of the ascending endograft (marked with A); (C) multiplanar reconstruction; (D) volume rendering reconstruction at 24 months.
P, Pseudoaneurysm; A, aorta.




PAUs lead to better outcomes, compared with endovascular
treatment of aneurysms or acute type A dissection.3,16-35
In a series on aneurysms, Kolvenbach and colleagues3
reported type 1 endoleaks, severe aortic incompetence,
kink and compression of the endograft, and overstenting
of the brachiocephalic artery. In acute type A dissection
series, additional stent grafting was reported in up to 40%
of cases, and type 1 endoleaks in 25% with a need for
reintervention in 50% of them, and a redissection rate of
nearly 7%.16,27,28
Technical aspects in TEVAR procedures are highly
critical, even in the ascending aorta, because it poses
several anatomical challenges, such as the mismatch
between lengths of the inner and outer curvatures, the dis-
tance from the sinotubular junction to the brachiocephalic
trunk, and the proximity of the coronary arteries. Thus, no
dedicated device is available for ascending TEVAR, and1610 The Journal of Thoracic and Cardiovascular Surmost of the published cases have been treated with the
off-label deployment of standard thoracic or abdominal
endografts.3-8,18-26 One method applied to address the
problem of various aortic lengths, is use of 2 or 3
stacked short endografts, namely abdominal aortic
extender cuffs; however, this option may lead to
problems such as dislodgment, migration, and
endoleaks.3,7 We used this technique in 3 cases because
the short neck length of these focal lesions facilitated
deployment of short standard endografts in urgent cases.
However, an additional type 3 endoleak occurred in our
experience. Another approach is implantation of standard
thoracic endografts. In those cases, it has been reported
to cut the standard thoracic endografts intraoperatively
after partial deployment on the operating table, and
reloaded it to optimize discrepancies in length
measurements.3gery c June 2016
FIGURE 3. Intraoperative angiography of an AAP (patient #5) shows the following: (A) the neck located in zone 2 (lines); (B) the deployment of 2 short
standard abdominal endografts; (C) final control angiogram with complete exclusion of the AAP and an absence of endoleaks; (D) preliminary CT-A of the
same AAP; (E) 12-month follow-up CT-A of the stable exclusion of the AAP with no endoleaks, and the full expansion and integrity of the endografts; (F)
volume rendering reconstruction at 24 months.




All these tricks underscore the limitations of current de-
vices, especially for lengthier lesions. Although expensive
and time consuming to manufacture, a custom-designed en-
dograft allows total endovascular treatment while
accommodating all the anatomical landmarks and variation
in size of the ascending aorta.4,23 For primarily this reason,
we planned to use a custom-designed endograft whenever
possible.
Another anatomical/technical factor needs to be taken into
consideration: The advancement and deployment of the en-
dograft over the aortic valve can result in temporary aortic
impairment, especially in patientswithmechanical valves.3,7
During this maneuver, temporary pacing was always
valuable, because it is rapid, controllable, and immediately
reversible. In addition, this approach allows a quick and
precise release of the endograft in zone 1 of the ascending
aorta, and limits the risk of distal migration.4,7,22,26
Advancement of the endograft is strongly related to
another important factor—the access vessel. This feature is
the only one that differs in our experience, compared
with the 2 largest published studies.7,8 In fact, although
all the procedures were performed with heparin forThe Journal of Thoracic and Caranticoagulation, TEE for deployment control and valve
competence, and rapid pacing (except in 1 case of full
cardiopulmonary bypass; 3.5% of 28 cases overall) for
precise deployment, they used different ‘‘remote’’ access
approaches, with a transapical approach used in most of
them, to make lesion engagement and endograft
deployment easier. The transapical approach in ascending
TEVAR has been advocated to overcome some limitations
of current ‘‘off-the-shelf’’ off-label devices that result from
the inadequate length of current delivery systems, and the
issues of retrograde passage across the arch and the various
lengths of the ascending aorta curvatures. Nevertheless, the
transapical approach has been recognized to be a
significant predictor of worse outcomes.36 Second, our le-
sions were suitable to be treated with more-remote and
less-invasive surgical approaches.20,29 Lastly, in our series,
3 (37.5%) patients had atrioventricular repair, 1 being
mechanical, which has been recognized as a clear
contraindication for the transapical approach, to avoid
valve impairment.
Given the unavailability of dedicated endografts, only
standard ‘‘off-the-shelf’’ devices were evaluated, in termsdiovascular Surgery c Volume 151, Number 6 1611
FIGURE 4. Preoperative (A and B) CT-A of a penetrating aortic ulcer of the ascending aorta (patient #8); postoperative (C and D) CT-A control showing
the presence of a type 3 endoleak. This patient had received a descending thoracic endovascular aortic repair before this ascending repair.




of sizing and immediate availability. Further, all these
factors have been matched with the need for a longer shaft.
Thus, at this time, use of a specific selection criterion is not
advisable. Considering the endograft deployment, and the
acute nature of most of these procedures, anatomical
feasibility dictates the choice of the endograft, as has
been the case since the first report of ascending TEVAR,
and for subsequent endovascular implants.
Infection is a known cause among etiologies of
AAPs.4,10,17 TEVAR for mycotic AAP has been used after
various types of major cardiac intervention: valve
replacement, orthotopic heart transplant, and coronary
artery bypass grafting.17,26,29 Although high-virulence
organisms grew in most of these cases, good results have
been reported, even in the urgent setting.26,29 In this
type of AAP, long-term follow-up remains a concern
because of the high risk of endograft infection. A recent
European multicenter collaboration study on endovascular
treatment of mycotic aortic aneurysms showed that 82%
of endograft-related infection occurred within the first
12 months, and can be fatal.17 All patients so far reported
to have been treated with ascending TEVAR for mycotic
AAPs have survived. In particular, Gelpi and colleagues26
and Heye and colleagues30 reported appropriate follow-up
CT imaging at 9 and 12 months after the procedure,1612 The Journal of Thoracic and Cardiovascular Surrespectively. Their AAPs were excluded, with progressive
shrinkage and no recurrence of infection. TEVAR,
combined with antibiotic therapy, may offer an alternative
to open repair, even with these high-risk mycotic
lesions.17,26
The increasing number of publications indicates the
popularity that TEVAR is gaining for use with ascending
aortic pathologies. Thrombin injection and endovascular
plugging have been widely described in treating AAPs,
but these approaches had inconsistent results.7,31,32
Fenestrated or branched endografts, flow-modulator stents,
and multiple-barrel grafts are novel, totally endovascular
strategies used to preserve supra-aortic branches in
ascending/arch TEVARs, but they are technically
demanding and thus are not widely reported.33-35Hybrid
repair increases operative landing zones and maintains
supra-aortic vessel patency, but it still requires open surgery
with extra-anatomical bypass.2 Branched endografts are a
new option adopted mainly for arch aneurysms, and these
endografts have been accompanied by clinical and technical
issues.21,24 Although current series are limited in number,
TEVAR can be a viable and available technical
alternative, because it can produce the same results and is
in keeping with the concepts of conventional prosthetic
reconstruction.gery c June 2016




Two important limitations of our study are the small num-
ber of patients, and use of midterm results. Both of these are
common in the available literature because we still consider
open repair the gold standard. The positive counterpart to
this limitation is that only focal lesions have been treated,
which provides morphological homogeneity.
CONCLUSIONS
In our experience, TEVAR for pseudoaneurysms and
PAUs of the ascending aorta was feasible, safe, and
effective. Appropriate patient selection for TEVAR in
the management of ascending aortic pathologies is crit-
ical, as are lesion selection and even endograft selection.
In these cases, satisfactory midterm results have
been observed in patients who are at highest or even pro-
hibitive risk, although long-term results need to be
confirmed.
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